Journal article icon

Journal article

Recombinant BCG expressing HTI prime and recombinant ChAdOx1 boost is safe and elicits HIV-1-specific T-cell responses in BALB/c mice

Abstract:

Despite the availability of anti-retroviral therapy, HIV-1 infection remains a massive burden on healthcare systems. Bacillus Calmette-Guérin (BCG), the only licensed vaccine against tuberculosis, confers protection against meningitis and miliary tuberculosis in infants. Recombinant BCG has been used as a vaccine vehicle to express both HIV-1 and Simian Immunodeficiemcy Virus (SIV) immunogens. In this study, we constructed an integrative E. coli-mycobacterial s...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.3390/vaccines7030078

Authors


More by this author
Role:
Author
ORCID:
0000-0003-4303-2443
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
ORCID:
0000-0002-6076-9546
More from this funder
Name:
Instituto de Salud Carlos III
Grant:
RETIC-RIS RD12/0017
FIS PI14/00494
More from this funder
Name:
Horizon 2020
Grant:
681137
More from this funder
Name:
European Commission
Grant:
681137
More from this funder
Name:
Medical Research Council
Grant:
MR/N023668/1
Publisher:
MDPI
Journal:
Vaccines More from this journal
Issue:
3
Publication date:
2019-08-02
Acceptance date:
2019-07-24
DOI:
EISSN:
2076-393X
ISSN:
2076-393X
Pmid:
31382453
Language:
English
Keywords:
Pubs id:
pubs:1040068
UUID:
uuid:ad88502b-b740-4e67-a4df-9a872a70ddeb
Local pid:
pubs:1040068
Source identifiers:
1040068
Deposit date:
2019-08-10

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP